Formulary and Therapeutic Interchanges
3rd Quarter 2024
| Class | Non-Preferred | Preferred Alternatives |
|---|---|---|
| Antidiabetics | Basaglar, Toujeo Max, Toujeo Solo, Admelog Solo, Mounjaro, Rybelsus | Insulin Glargine, Insulin Lisp, Insulin Lispro Kwik, Insulin Aspart, Insulin Aspart Kwik, Trulicity*, Ozempic* |
| Stimulants and Related ADHD Drugs | Focalin XR, Focalin, Adhansia Xr, Aptensio XR, Jornay PM, Mydayis, Strattera, Intuniv | Dexmethylphenidate, Dexmethylphenidate ER, Concerta, Methylin, Methylphenidate, Quillichew, Quillivant, Atomoxetine, Guanfacine, Qelbree |
| Antiasthmatic and Bronchodilator Agents | Budesonide/ formoterol, Proair Respiclick, Fluticasone/ salmeterol, Wixela Inhub, Budesonide | Symbicort, Albuterol HFA, Advair Diskus, Advair HFA, Spiriva, Pulmicort |
| Antidepressants | Forfivo Xl, Trintellix, Desvenlafaxine, Vilazodone | Bupropion Hcl, Fluoxetine, Venlafaxine, Escitalopram |
| Gastrointestinal Agents - Misc. | Canasa, Lubiprostone, Sevelamer | Apriso, Lialda, dexlansoprazole, Amitiza, Renvela |
*May require Prior Authorization
Abbreviations: ER = extended-release, XR = extended-release